Go Deep
Anika Therapeutics, Inc.
Anika Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,496 | -89.3 | 2.00 | 0.18 | 1,955.15 |
| Oct 2026 | 18,572 | -88.0 | 1.97 | 0.18 | 1,922.69 |
| Oct 2026 | 18,452 | -90.0 | 2.02 | 0.18 | 1,964.74 |
| Oct 2026 | 18,645 | -86.9 | 1.95 | 0.18 | 1,892.40 |
| Oct 2026 | 18,580 | -87.9 | 1.97 | 0.18 | 1,917.19 |
| Oct 2026 | 18,520 | -88.9 | 1.99 | 0.18 | 1,938.05 |
| Oct 2026 | 18,477 | -89.6 | 2.01 | 0.18 | 1,948.39 |
| Oct 2026 | 18,344 | -91.7 | 2.06 | 0.18 | 1,990.70 |
Anika Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 32,610,000.0 | 29,612,000.0 | 30,615,000.0 | 27,817,000.0 |
| Net Profit | 3,309,000.0 | -5,056,000.0 | 292,000.0 | -2,329,000.0 |
| EPS | 0.2 | -0.4 | 0.0 | -0.2 |
Anika Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 112,819,000.0 | 119,907,000.0 | 120,792,000.0 | 113,827,000.0 | — |
| Net Profit | -10,880,000.0 | -56,385,000.0 | -82,667,000.0 | -14,859,000.0 | — |
| EPS | -0.8 | -3.8 | -5.6 | -1.0 | — |
Anika Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 190,270,000.0 | 202,740,000.0 | 270,632,000.0 | 349,128,000.0 | — |
| Total Liabilities | 46,805,000.0 | 48,751,000.0 | 58,367,000.0 | 63,565,000.0 | — |
| Total Equity | 143,465,000.0 | 153,989,000.0 | 212,265,000.0 | 285,563,000.0 | — |
Owes vs Owns
Anika Therapeutics, Inc. owed $0.25 for every $1 it owned in Jun 2026, up from $0.18 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.25× | 0.25× | 0.24× | 0.22× | 0.18× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Anika Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 30.2%Receivables 12.5%Inventory 9.9%Fixed assets (tangible) 34.8%Intangible assets 5.1%Other assets 7.5%
How it's funded — Dec 2025
Short-term debt 1.1%Long-term debt 12.7%Payables 3.2%Other liabilities 7.6%Shareholders' equity 75.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 57.5 | 55.6 | 68.7 | 86.3 |
| Receivables | 23.7 | 23.6 | 26.4 | 34.6 |
| Inventory | 18.8 | 23.8 | 24.4 | 39.8 |
| Fixed assets (tangible) | 66.3 | 64.7 | 65.0 | 79.0 |
| Intangible assets | 9.7 | 9.6 | 10.1 | 81.9 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 14.3 | 25.4 | 76.0 | 27.5 |
| Liabilities & equity | ||||
| Short-term debt | 2.1 | 1.9 | 1.8 | 2.1 |
| Long-term debt | 24.2 | 24.0 | 25.9 | 28.8 |
| Payables | 6.0 | 5.6 | 6.2 | 9.1 |
| Other liabilities | 14.5 | 17.2 | 24.4 | 23.6 |
| Shareholders' equity | 143.5 | 154.0 | 212.3 | 285.6 |
| Net tangible assets | 133.8 | 144.4 | 202.1 | 203.6 |
Anika Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 11,188,000.0 | 5,403,000.0 | -1,788,000.0 | 4,409,000.0 | — |
| Investing Activities | -401,000.0 | -8,334,000.0 | -5,427,000.0 | -7,486,000.0 | — |
| Financing Activities | -10,551,000.0 | -12,729,000.0 | -6,324,000.0 | -4,852,000.0 | — |